Company intelligence / Profile preview
RAM Pharmaceuticals
- Ownership
- Private
- Employees
- ~125
- Development stage
- Other
Overview
The US-based RAM Pharmaceuticals focuses on specialty pharmaceutical products for oncology supportive care and oral health. Its pipeline includes Triamdocaine, currently in Phase 2 clinical trials for severe oral mucositis, and Acyclonine MUM, a commercially available compounded medication for various painful oral conditions. The Jordan-based RAM Pharma is an established generic drug manufacturer with ISO9001 certification, producing a wide range of over-the-counter and prescription pharmaceuticals. It operates at commercial scale, supplying domestic markets and exporting to several countries.
- Therapeutic areas
- NeurologyMetabolic DisordersPulmonologyInfectious DiseasesDermatologyGastroenterologyEndocrinologyOncologyOtherRheumatologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on RAM Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAM Pharmaceuticals.